The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure.

[1]  R. Brant,et al.  Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. , 2001, JAMA.

[2]  Lawrence Joseph,et al.  β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis , 2001 .

[3]  J. Tu,et al.  Rate of heart failure and 1-year survival for older people receiving low-dose β-blocker therapy after myocardial infarction , 2000, The Lancet.

[4]  M. Nichaman,et al.  Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. , 2000, Archives of internal medicine.

[5]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[6]  E. Philbin,et al.  Clinical outcomes in heart failure: report from a community hospital-based registry. , 1999, The American journal of medicine.

[7]  Moskowitz,et al.  beta-Blockers in congestive heart failure. , 1999 .

[8]  P. Armstrong,et al.  Insights into the contemporary epidemiology and outpatient management of congestive heart failure. , 1999, American heart journal.

[9]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[10]  K. Bailey,et al.  Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. , 1998, Circulation.

[11]  B. Massie.  15 years of heart-failure trials: what have we learned? , 1998, The Lancet.

[12]  S. Viskin,et al.  β-Blocker Dosages and Mortality After Myocardial Infarction: Data From a Large Health Maintenance Organization , 1998 .

[13]  S. Yusuf.  Digoxin in heart failure: results of the recent Digoxin Investigation Group trial in the context of other treatments for heart failure. , 1997, European heart journal.

[14]  L Goldman,et al.  Correlates of early hospital readmission or death in patients with congestive heart failure. , 1997, The American journal of cardiology.

[15]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[16]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[17]  C. Naylor,et al.  Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. , 1996, Journal of the American College of Cardiology.

[18]  C D Naylor,et al.  Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. , 1995, JAMA.

[19]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[20]  J. Hampton,et al.  Evidence of inadequate investigation and treatment of patients with heart failure. , 1994, British heart journal.

[21]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[22]  T. Smith.  Digoxin in heart failure. , 1993, The New England journal of medicine.

[23]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[24]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[25]  M S Kramer,et al.  Scientific challenges in the application of randomized trials. , 1984, JAMA.

[26]  H. Ikram,et al.  DOUBLE-BLIND TRIAL OF CHRONIC ORAL BETA BLOCKADE IN CONGESTIVE CARDIOMYOPATHY , 1981, The Lancet.